These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 32461811)

  • 1. The role of gut microbiota in liver disease development and treatment.
    Wang L; Wan YY
    Liver Res; 2019 Mar; 3(1):3-18. PubMed ID: 32461811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
    Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
    Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbiota, fatty liver disease, and hepatocellular carcinoma.
    Chu H; Williams B; Schnabl B
    Liver Res; 2018 Mar; 2(1):43-51. PubMed ID: 30416839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
    Han R; Ma J; Li H
    Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms by Which Probiotic Bacteria Attenuate the Risk of Hepatocellular Carcinoma.
    Thilakarathna WPDW; Rupasinghe HPV; Ridgway ND
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbiota, NASH, HCC and the potential role of probiotics.
    Brandi G; De Lorenzo S; Candela M; Pantaleo MA; Bellentani S; Tovoli F; Saccoccio G; Biasco G
    Carcinogenesis; 2017 Mar; 38(3):231-240. PubMed ID: 28426878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered gut microbiota in hepatocellular carcinoma: Insights into the pathogenic mechanism and preclinical to clinical findings.
    Das BK
    APMIS; 2022 Dec; 130(12):719-740. PubMed ID: 36321381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response.
    Delaune V; Orci LA; Lacotte S; Peloso A; Schrenzel J; Lazarevic V; Toso C
    Expert Opin Biol Ther; 2018 Oct; 18(10):1061-1071. PubMed ID: 30173562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.
    Milosevic I; Vujovic A; Barac A; Djelic M; Korac M; Radovanovic Spurnic A; Gmizic I; Stevanovic O; Djordjevic V; Lekic N; Russo E; Amedei A
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the microbiome in NAFLD and NASH.
    Kolodziejczyk AA; Zheng D; Shibolet O; Elinav E
    EMBO Mol Med; 2019 Feb; 11(2):. PubMed ID: 30591521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm.
    Ghoshal UC; Goel A; Quigley EMM
    Indian J Gastroenterol; 2020 Feb; 39(1):9-21. PubMed ID: 32291578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
    Meroni M; Longo M; Dongiovanni P
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan.
    Tokushige K; Hashimoto E; Kodama K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():88-92. PubMed ID: 24251711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.
    Ma J; Zhou Q; Li H
    Nutrients; 2017 Oct; 9(10):. PubMed ID: 29035308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
    Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH
    Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis.
    Plaza-Díaz J; Solis-Urra P; Aragón-Vela J; Rodríguez-Rodríguez F; Olivares-Arancibia J; Álvarez-Mercado AI
    Biomedicines; 2021 Feb; 9(2):. PubMed ID: 33546191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis.
    Delzenne NM; Knudsen C; Beaumont M; Rodriguez J; Neyrinck AM; Bindels LB
    Proc Nutr Soc; 2019 Aug; 78(3):319-328. PubMed ID: 30628563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic fatty liver and the gut microbiota.
    Bashiardes S; Shapiro H; Rozin S; Shibolet O; Elinav E
    Mol Metab; 2016 Sep; 5(9):782-94. PubMed ID: 27617201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.